Epivir

(Lamivudine)

ApprovedSmall molecule

Lamivudine is used to treat HIV infection and chronic hepatitis B by slowing down the reproduction of these viruses in the body, helping to reduce viral load and improve immune function.[2] Epivir is currently approved and in use across 32 indications[4].[1]

Epivir is one of 678 small molecule programs targeting Viral Disease. It is currently in Approved.

Indications

249

Total Trials

Active Trials

677

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Viral DiseaseActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

HepatitisActive, not recruiting

Bone DensityActive, not recruiting

Immunodeficiency DiseaseActive, not recruiting

Hepatitis B Virus InfectionActive, not recruiting

Alzheimer DiseaseApproved

Kaposi's SarcomaApproved

Colorectal CancerApproved

HIV-Associated NephropathyApproved

Viral DiseaseApproved

Active, not recruiting

Chronic Lymphocytic LeukemiaPreclinical

Active, not recruiting

HepatitisApproved

Active, not recruiting

Bone DensityPreclinical

Active, not recruiting

Immunodeficiency DiseaseApproved

Active, not recruiting

Hepatitis B Virus InfectionApproved

Active, not recruiting

Alzheimer DiseaseApproved

Approved

Kaposi's SarcomaApproved

Approved

Colorectal CancerApproved

Approved

HIV-Associated NephropathyApproved

Approved

Showing 10 of 32 indications

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Epivir

GGlaxo Dba Glaxosmithkline

Approved

17 2

Biltricide

Bayer

Preclinical

4 3

Emtriva

Gilead

Preclinical

1 4

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 5

Theo-Dur

Pfizer

Preclinical

1 6

Minipress

Pfizer

Preclinical

1 7

Niclocide

Bayer

Preclinical

1 8

Alfenta

Jazz Pharmaceuticals

Preclinical

1 9

Intuniv

PPromius Pharma, LLC

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

HBV Infection

NCT06503796

Q3 2027

Phase 2Recruiting

Small Cell Lung Cancer

NCT04696575

Q2 2029

Phase 2/3Active, not recruiting

Treatment

NCT02369406

Clinical

Trials by Indication[1]

Effectiveness23 trials

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00002371·80 enrolled

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001108·6 enrolled

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001091·200 enrolled

Show 20 more trials

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

Suspended· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002424·186 enrolled

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

Completed· GSK logo

GSK··NCT04019873·774 enrolled

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000922·1,710 enrolled

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002376·540 enrolled

Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00050895·775 enrolled

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002451·8 enrolled

A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000916·399 enrolled

Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Completed· Gilead logo

Gilead·Phase 2·NCT00002234·25 enrolled

The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT00002368·2,000 enrolled

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00005918·730 enrolled

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

Completed· AbbVie logo

AbbVie··NCT02581202·216 enrolled

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002442

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002179·200 enrolled

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Completed·AAbbott·Phase 2·NCT00038220·40 enrolled

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001067·105 enrolled

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002391

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002241·80 enrolled

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000901·24 enrolled

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

Completed· GSK logo

GSK·Phase 3·NCT00002436·325 enrolled

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002389·210 enrolled

Chronic Hepatitis20 trials

A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone

Completed· GSK logo

GSK·Phase 4·NCT00354653·100 enrolled

Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir

Completed·—·Phase 4·NCT01023217·90 enrolled

Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

Unknown status·—·Phase 4·NCT02482272·90 enrolled

Show 17 more trials

Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

Completed· GSK logo

GSK·Phase 3·NCT00140725·160 enrolled

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Completed· Roche logo

Roche·Phase 3·NCT01095835·131 enrolled

Lamivudine for Chronic Hepatitis B

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001457·60 enrolled

A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

Completed· Roche logo

Roche·Phase 4·NCT02598063·255 enrolled

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

Completed· Gilead logo

Gilead·Phase 3·NCT00095121·173 enrolled

Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects

Completed·SSoutheast University, China·Phase 4·NCT02202473·192 enrolled

Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

Completed· Novartis logo

Novartis·Phase 3·NCT00131742

Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT01005238·27 enrolled

A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT00393484·122 enrolled

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Completed· Novartis logo

Novartis·Phase 3·NCT00076336·232 enrolled

An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

Completed· Novartis logo

Novartis·Phase 2·NCT00124241

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00410202·629 enrolled

Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation

Unknown status·KKaohsiung Veterans General Hospital.·Phase 3·NCT01848743·120 enrolled

Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00120796·8 enrolled

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Completed· Roche logo

Roche·Phase 3·NCT02263079·62 enrolled

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Terminated·IInje University·Phase 4·NCT00798460·30 enrolled

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01438424·1,053 enrolled

Drug19 trials

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00014937·240 enrolled

Once-Daily Drug Regimen for HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001968·25 enrolled

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

Completed·RRhonda Brand·Phase 1·NCT04302896·30 enrolled

Show 16 more trials

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00074581·3,526 enrolled

A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002369·200 enrolled

A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002227·60 enrolled

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002401·160 enrolled

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 4·NCT00005106·230 enrolled

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00102206·6 enrolled

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

Completed·WWeill Medical College of Cornell University·N/A·NCT00002407

Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination

Completed·TTriangle Pharmaceuticals·Phase 3·NCT00002416·390 enrolled

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002411

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002400·45 enrolled

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

Completed·BBabafemi Taiwo·Phase 3·NCT02263326·89 enrolled

A Study of Two Anti-HIV Drug Combinations

Completed· GSK logo

GSK·N/A·NCT00002203

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Unknown status· GSK logo

GSK·Phase 3·NCT00009061·624 enrolled

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002410

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002168·200 enrolled

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

Completed· GSK logo

GSK·Phase 2·NCT00002423·100 enrolled

Treatment12 trials

A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Roche logo

Roche·Phase 3·NCT00002367·40 enrolled

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000885·440 enrolled

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158405·840 enrolled

Show 9 more trials

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

Completed·FFundacion IDEAA·Phase 4·NCT04549467·244 enrolled

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

Completed·UUniversity Hospital Virgen de las Nieves··NCT04002323·88 enrolled

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Completed· GSK logo

GSK·Phase 3·NCT02831764·722 enrolled

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02249130·18 enrolled

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Completed· GSK logo

GSK·Phase 3·NCT02831673·719 enrolled

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT02582684·122 enrolled

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

Completed·TThe University of Hong Kong·N/A·NCT01013272·50 enrolled

Early Infant HIV Treatment in Botswana

Active, not recruiting·HHarvard School of Public Health (HSPH)·Phase 2/3·NCT02369406·67 enrolled

Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation

Terminated·TTaichung Veterans General Hospital·Phase 4·NCT01627223·17 enrolled

HIV infection12 trials

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

Completed·UUniversity of North Carolina, Chapel Hill·N/A·NCT02384395·40 enrolled

Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT03205566·38 enrolled

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00013520·1,125 enrolled

Show 9 more trials

Effectiveness of Anti-HIV Drugs in Patients Who Have Not Received Previous Anti-HIV Drugs During Different Stages of HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006443·24 enrolled

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Completed· GSK logo

GSK·Phase 1·NCT00002183·60 enrolled

A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000870·200 enrolled

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

Completed· GSK logo

GSK·Phase 2·NCT00002233·30 enrolled

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

Terminated·AAvexa·Phase 2/3·NCT00612898·239 enrolled

Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001644·42 enrolled

A Phase I Study of Methotrexate for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000834·30 enrolled

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00102960·377 enrolled

65 more indications

LAM7 trials

REal-Life Cohort With DOlutegravir + LAmivudina

Completed·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz··NCT04638686·185 enrolled

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Completed· GSK logo

GSK·Phase 1·NCT02738931·30 enrolled

3TC (Lamivudine; GR109714X) Open-Label Program

Completed· GSK logo

GSK·N/A·NCT00002108

Show 4 more trials

Lamivudine and Adefovir Dipivoxil Fixed Dose Combination

Completed· GSK logo

GSK·Phase 1·NCT01353742·40 enrolled

Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000882·300 enrolled

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Completed· GSK logo

GSK·Phase 1·NCT03078556·154 enrolled

Entecavir Plus Adefovir in Lamivudine-Resistant Patients

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT00986778

Hepatitis B7 trials

Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus

Completed·HHua Zhang·Phase 4·NCT01788371·700 enrolled

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA

Completed·PPusan National University Hospital·Phase 4·NCT00637663·72 enrolled

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Unknown status·FFudan University·Phase 2·NCT01914744·82 enrolled

Show 4 more trials

Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

Completed·—·Phase 4·NCT01743079·700 enrolled

A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers

Completed·HHospital Authority, Hong Kong·N/A·NCT00516945·110 enrolled

A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B

Completed·MMaulana Azad Medical College·Phase 4·NCT00380614

Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00051090

HIV6 trials

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

Completed· GSK logo

GSK·Phase 3·NCT00046176·240 enrolled

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

Completed· GSK logo

GSK·Phase 3·NCT00002320·320 enrolled

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000841·1,750 enrolled

Show 3 more trials

A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 3·NCT00002195·290 enrolled

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001085·94 enrolled

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

Completed· GSK logo

GSK·Phase 4·NCT00005764·100 enrolled

Children5 trials

Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00312091·44 enrolled

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00234091·300 enrolled

Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00672412·42 enrolled

Show 2 more trials

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000865·32 enrolled

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001066·740 enrolled

Pregnant Women4 trials

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000888·14 enrolled

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000887·24 enrolled

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000944·24 enrolled

Show 1 more trial

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000878·26 enrolled

Immunodeficiency4 trials

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

Terminated· GSK logo

GSK·Phase 2·NCT04900038·85 enrolled

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00350272·76 enrolled

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT03272347·123 enrolled

Show 1 more trial

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00799864·54 enrolled

HIV-14 trials

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

Completed·RRadboud University Medical Center·Phase 2·NCT00943540·20 enrolled

A Six-Month Safety and Antiviral Study in HIV-1 Seropositive, AZT-Experienced Patients With CD4 Counts Less Than or Equal to 50 Cells/mm3 to Evaluate MK-639 Alone Versus Zidovudine (AZT) and 3TC Versus the Combination of MK-639 With AZT/3TC

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002155·600 enrolled

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 3·NCT00044577·166 enrolled

Show 1 more trial

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002378·825 enrolled

Efficacy and Safety3 trials

Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00640263·1,500 enrolled

Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00273975·123 enrolled

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01620944·3 enrolled

Tenofovir3 trials

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02945163·184 enrolled

Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

Completed·FFundacion SEIMC-GESIDA·Phase 4·NCT02159599·249 enrolled

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects

Completed·FFundación Huésped·Phase 4·NCT02770508·145 enrolled

Randomized2 trials

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Completed· Roche logo

Roche·Phase 2·NCT00002162·140 enrolled

A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002208·400 enrolled

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06811246·20 enrolled

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Completed· GSK logo

GSK·Phase 4·NCT02634073·16 enrolled

Tics2 trials

Pharmacokinetics of Lamivudine at Two Different Doses

Completed·KKirby Institute·Phase 1/2·NCT00985647·24 enrolled

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Terminated·RRadboud University Medical Center·Phase 2·NCT02566707·9 enrolled

Immune System2 trials

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled

Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00004855·55 enrolled

Chemotherapy2 trials

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000899·10 enrolled

A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy

Unknown status·HHospital Authority, Hong Kong·N/A·NCT00489151·70 enrolled

Drug Therapy2 trials

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000923·110 enrolled

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

Completed·AAbbott·Phase 3·NCT00004583·660 enrolled

Malaria2 trials

Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group·Phase 1·NCT00719602·105 enrolled

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

Completed·UUniversity of California, San Francisco·Phase 3·NCT00993031·389 enrolled

Pregnancy2 trials

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000920·24 enrolled

The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children

Unknown status·—··NCT02301650·400 enrolled

Resistance2 trials

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000838·256 enrolled

3TC or No 3TC for HIV With 3TC Resistance

Suspended·UUniversity of British Columbia·Phase 4·NCT00143728·152 enrolled

Combination Therapy2 trials

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006617·25 enrolled

Study of Options for Second-Line Effective Combination Therapy (SELECT)

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT01352715·515 enrolled

Phase II1 trial

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Completed· Roche logo

Roche·Phase 2·NCT00002190·30 enrolled

Lipodystrophy1 trial

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00006190

Kidney Transplant1 trial

Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.

Terminated·NNational Taiwan University Hospital·Phase 4·NCT02894554·19 enrolled

Drug Interactions1 trial

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen

Terminated·JJudit Pich·Phase 3·NCT03333083·17 enrolled

Liver Disease1 trial

Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients

Unknown status·YYonsei University·Phase 4·NCT00823550·462 enrolled

Advanced1 trial

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 4·NCT00342355·1,771 enrolled

Hepatitis C1 trial

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

Completed· Pfizer logo

Pfizer·Phase 4·NCT00141284·12 enrolled

Retinal Detachment1 trial

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT06056596·2 enrolled

Solid Organ Transplant1 trial

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 4·NCT03360682·19 enrolled

Prevention1 trial

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention

Completed·AANRS, Emerging Infectious Diseases·Phase 3·NCT03870438·1,506 enrolled

Child1 trial

Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV

Unknown status·AANRS, Emerging Infectious Diseases·Phase 2·NCT03869944·97 enrolled

Aicardi-Goutières syndrome1 trial

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome

Completed·UUniversity of Edinburgh·Phase 2·NCT04731103·13 enrolled

Efficacy1 trial

Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02181933·2,648 enrolled

Cognitive impairment1 trial

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Active, not recruiting·FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·Phase 2·NCT06519357·23 enrolled

Liver Cancer1 trial

Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery

Unknown status·FFudan University·Phase 3·NCT01936233·112 enrolled

Infants1 trial

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana

Completed·—··NCT04862975·164 enrolled

Drug Resistance1 trial

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120783·40 enrolled

Single Dose1 trial

Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group·Phase 2·NCT00307151·452 enrolled

Fat Metabolism1 trial

A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients

Completed· GSK logo

GSK·Phase 3·NCT00002245

Impaired Renal Function1 trial

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT02116660·11 enrolled

Kidney Disease1 trial

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease

Completed· Roche logo

Roche·Phase 3·NCT00002397·24 enrolled

CLE1 trial

Nucleosides And Darunavir/Dolutegravir In Africa

Unknown status·MMakerere University·Phase 3·NCT03988452·465 enrolled

Chronic Hepatitis B Virus Infection1 trial

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00034359·79 enrolled

Chronic HBV Infection1 trial

Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection

Unknown status·SSun Yat-sen University·Phase 4·NCT00810524·600 enrolled

Intensive Care1 trial

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00028327·250 enrolled

Clinical Trial1 trial

Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

Completed·—·Phase 4·NCT02431975·73 enrolled

Double-blind1 trial

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

Completed·PPharmacia and Upjohn·Phase 3·NCT00002124·1,250 enrolled

Treatment Failure1 trial

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000918·300 enrolled

Newborns1 trial

Antiretroviral Regime for Viral Eradication in Newborns

Completed·NNational Center for Women and Children's Health, China CDC·Phase 4·NCT02712801·600 enrolled

Long-term Follow-up1 trial

2NN & CHARM Long-Term Follow-up Study

Completed·IInternational Antiviral Therapy Evaluation Center·Phase 4·NCT00127972·763 enrolled

Metastatic Colorectal Cancer1 trial

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT03144804·36 enrolled

Itching1 trial

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

Completed·JJudit Pich·Phase 3·NCT03311945·33 enrolled

Adolescent1 trial

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

Completed· Tibotec Pharmaceuticals, Ireland logo

Tibotec Pharmaceuticals, Ireland·Phase 2·NCT00915655·12 enrolled

HBV Infection1 trial

Antiviral Therapy in Infants With HBV Infection

Not yet recruiting·—·Phase 4·NCT06503796·60 enrolled

ART1 trial

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00312039·20 enrolled

Hemophilia1 trial

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002386·55 enrolled

Immune Response1 trial

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006578

Cirrhosis1 trial

Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)

Completed· GSK logo

GSK··NCT01376154·342 enrolled

Small Cell Lung Cancer1 trial

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT04696575·28 enrolled

Lymphoma1 trial

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT01528865

Disease Progression1 trial

A Study of Disease Progression and Anti-HIV Treatments

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001068·210 enrolled

Vaccination1 trial

Effect of Vaccination on Turnover of Lamivudine (3TC) Sensitive and Resistant Virus Populations in HIV-1-Infected Individuals

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001080

Liver1 trial

Strategies for Delivering Anti-HIV Therapy in South Africa

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00080522·813 enrolled

Unspecified4 trials

An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

Unknown status·RRuijin Hospital·Phase 4·NCT02560649·324 enrolled

ANRS 12372 MODERATO Study

Unknown status·AANRS, Emerging Infectious Diseases·Phase 3·NCT04022967·480 enrolled

Test Albuvirtide in Experienced Patients

Completed·FFrontier Biotechnologies Inc.·Phase 3·NCT02369965·418 enrolled

Show 1 more trial

Optimization of Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02935075·184 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 17, 1995

EPIVIR

NDA NDA020596

Nov 17, 1995

EPIVIR

NDA NDA020564

Dec 8, 1998

EPIVIR-HBV

NDA NDA021004

Dec 8, 1998

EPIVIR-HBV

NDA NDA021003

Sources

References

[1]
ClinicalTrials.gov — 249 trial records for Lamivudine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Epivir drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Lamivudine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Lamivudine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021004). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor; DNA Polymerase/reverse Transcriptase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Epivir

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q2 2029

Trials by Indication[1]

Effectiveness23 trials

Chronic Hepatitis20 trials

Drug19 trials

Treatment12 trials

HIV infection12 trials

LAM7 trials

Hepatitis B7 trials

HIV6 trials

Children5 trials

Pregnant Women4 trials

Immunodeficiency4 trials

HIV-14 trials

Efficacy and Safety3 trials

Tenofovir3 trials

Randomized2 trials

Tuberculosis2 trials

Antiretroviral Treatment2 trials

Interaction2 trials

Tics2 trials

Immune System2 trials

Chemotherapy2 trials

Drug Therapy2 trials

Malaria2 trials

Pregnancy2 trials

Resistance2 trials

Combination Therapy2 trials

Phase II1 trial

Lipodystrophy1 trial

Kidney Transplant1 trial

Drug Interactions1 trial

Liver Disease1 trial

Advanced1 trial

Hepatitis C1 trial

Retinal Detachment1 trial

Solid Organ Transplant1 trial

Prevention1 trial

Child1 trial

Aicardi-Goutières syndrome1 trial

Efficacy1 trial

Cognitive impairment1 trial

Liver Cancer1 trial

Infants1 trial

Drug Resistance1 trial

Single Dose1 trial

Fat Metabolism1 trial

Impaired Renal Function1 trial

Kidney Disease1 trial

CLE1 trial

Chronic Hepatitis B Virus Infection1 trial

Chronic HBV Infection1 trial

Intensive Care1 trial

Clinical Trial1 trial

Double-blind1 trial

Treatment Failure1 trial

Newborns1 trial

Long-term Follow-up1 trial

Metastatic Colorectal Cancer1 trial

Itching1 trial

Adolescent1 trial

HBV Infection1 trial

ART1 trial

Hemophilia1 trial

Immune Response1 trial

Cirrhosis1 trial

Small Cell Lung Cancer1 trial

Lymphoma1 trial

Disease Progression1 trial

Vaccination1 trial

Liver1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References